Drug Trial Radar · NCT02430194
Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Dec 2014
Primary completion
Apr 18, 2017
Study completion Jun 15, 2017
Sponsor
- Lead sponsor
- EIT Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Ankara University
- First posted
- Apr 30, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Open-label, Dose-ranging Study to Evaluate the Safety and Efficacy of Lonafarnib with Ritonavir Boosting +/- Peginterferon alfa-2a in Patients Chronically Infected with Delta Hepatitis (HDV) (LOWR-2).
Conditions
- Chronic Hepatitis D Infection
Interventions
lonafarnibDrug
antiviral farnesyl transferase inhibitor
ritonavirDrug
CYP 3A4 inhibitor, lonafarnib booster
Pegylated interferon-alfa-2aDrug
immunomodulator
Primary outcomes
What the sponsor says the trial is designed to measure.
- ≥2 log10 Decline of HDV RNA From Baseline at End of Treatment (EOT)Time frame: 12-48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ankara University Medical School
Ankara, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.